Back to search results

Genetic Variation and Risk for Persistent Pulmonary Hypertension of the Newborn

This study is looking into why some babies develop Persistent Pulmonary Hypertension of the Newborn (PPHN) after their mothers take common pain medicines called NSAIDs (non-steroidal anti-inflammatory drugs) during pregnancy. PPHN is a serious condition where a baby's lungs don't adapt properly after birth. Researchers want to see if a specific gene, called PTGS-1, has variations that make some babies more likely to get PPHN when exposed to NSAIDs. The study aims to compare the PTGS-1 gene in babies with PPHN and healthy babies. They will follow participants for about 3 weeks during their hospital stay. This study is currently unclear on its status and plans to include 200 infants.

Study design
This is an observational study, meaning researchers will observe and collect information from 200 infants. It is not a treatment study.
What's involved
Participants will be followed for the duration of their hospital stay, which is expected to be an average of 3 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the duration of hospital stay, an expected average of 3 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00710177

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Recruiting
Not specifiedUp to 12Observational
Medical College of Wisconsin
~200 participants
Updated 2026-01-26 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero.
Measured over participants will be followed for the duration of hospital stay, an expected average of 3 weeks

Conditions

Persistent Pulmonary Hypertension of the Newborn

Explore related trials

Persistent Fetal Circulation

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • G. Ganesh Konduri, MD · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

G. Ganesh Konduri, MD
[email protected]
414-266-6820
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.

Exclusion

Patients will be excluded if they are diagnosed with lethal congenital anomalies
structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
structural gastrointestinal tract abnormality that could interfere with meconium passage
congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

What this trial measures

  • To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero.participants will be followed for the duration of hospital stay, an expected average of 3 weeks